Concepedia

Publication | Closed Access

The VIVA Trial

DOI

1K

Citations

18

References

2003

Year

Timothy D. Henry, Brian H. Annex, George R. McKendall, Michael Azrin, John J. López, Frank J. Giordano, PK Shah, James T. Willerson, Raymond L. Benza, Daniel S. Berman,
Circulation

Abstract

rhVEGF seems to be safe and well tolerated. rhVEGF offered no improvement beyond placebo in all measurements by day 60. By day 120, high-dose rhVEGF resulted in significant improvement in angina and favorable trends in ETT time and angina frequency.

References

YearCitations

Page 1